Key Points
- Director Alexander Gold sold 6,933 shares on Nov. 12 at an average price of $46.72, totaling $323,909.76, according to an SEC filing.
- MLYS traded down to $38.65 on heavy volume (2,156,802 shares vs. a 1,141,032 average); the company has a market cap of about $3.06 billion and a 52‑week range of $8.24–$47.65.
- Mineralys reported Q3 EPS of ($0.52), beating estimates of ($0.66), and the stock carries an average analyst stance of "Moderate Buy" with a $46.67 price target.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Alexander Gold sold 6,933 shares of the firm's stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $46.72, for a total value of $323,909.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Mineralys Therapeutics Price Performance
MLYS stock traded down $5.64 on Friday, reaching $38.65. 2,156,802 shares of the company traded hands, compared to its average volume of 1,141,032. The firm has a fifty day simple moving average of $40.05 and a 200-day simple moving average of $23.78. The company has a market cap of $3.06 billion, a P/E ratio of -13.26 and a beta of 0.40. Mineralys Therapeutics, Inc. has a one year low of $8.24 and a one year high of $47.65.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.66) by $0.14. On average, sell-side analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.
Institutional Investors Weigh In On Mineralys Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. grew its stake in Mineralys Therapeutics by 297.5% during the 1st quarter. SBI Securities Co. Ltd. now owns 1,590 shares of the company's stock valued at $25,000 after purchasing an additional 1,190 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Mineralys Therapeutics by 51.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,518 shares of the company's stock worth $34,000 after purchasing an additional 850 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company's stock valued at $40,000 after buying an additional 676 shares during the period. Ameritas Investment Partners Inc. grew its holdings in shares of Mineralys Therapeutics by 42.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,995 shares of the company's stock valued at $54,000 after purchasing an additional 1,197 shares during the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in Mineralys Therapeutics during the 2nd quarter valued at approximately $91,000. Hedge funds and other institutional investors own 84.46% of the company's stock.
Analyst Ratings Changes
Several brokerages have recently issued reports on MLYS. Wall Street Zen upgraded shares of Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, August 22nd. HC Wainwright raised their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday. Wells Fargo & Company boosted their target price on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Tuesday. The Goldman Sachs Group raised their target price on shares of Mineralys Therapeutics from $32.00 to $52.00 and gave the stock a "buy" rating in a research note on Tuesday, September 9th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Mineralys Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $46.67.
Read Our Latest Analysis on Mineralys Therapeutics
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
